Fisher Nets Apogent Diagnostic Business: Combined Revenue To Top $1 Bil.
This article was originally published in The Gray Sheet
Executive Summary
Fisher Scientific will add consumables used in immunodiagnostic products and drugs-of-abuse testing to its diagnostics portfolio through a $3.7 bil. merger with Apogent